420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180


Image for About NeoStem

About NeoStem

NeoStem develops and manufactures cell therapies for its proprietary technology platforms and for the cell therapy industry.

Learn More



Image for Cancer Immunotherapy

Cancer Immunotherapy

NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.

Learn More 

Enhancingthe body’s healing response

Image for Ischemic Repair

Ischemic Repair

NeoStem is developing therapies to repair ischemia through the development and formation of new blood vessels.

Learn More

Rebalancingthe immune system

Image for Immune Modulation

Immune Modulation

NeoStem seeks to develop cell therapies using a person’s own immune cells as a therapeutic product to treat disorders of the immune system.

Learn More

Unlockingthe power of VSELs

Image for Tissue Regeneration

Tissue Regeneration

NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.

Learn More

Leveragingexperience in cell therapy

Image for Contract Manufacturing

Contract Manufacturing

NeoStem’s subsidiary, PCT, provides outsourced manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.

Learn More

News + Events

News + Events

NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine November 25, 2014 - Learn More
NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial November 21, 2014 - Learn More
Investor Call on PreSERVE AMI Phase 2 Data November 18, 2014 - Learn More

NeoStem Blog

Encouraging Findings from PreSERVE AMI

As the Chief Visionary Officer and a Director of NeoStem, and as one of the inventors of the core technolog.... Read More

PreSERVE AMI Phase 2 Results

Yesterday, Dr. Arshed Quyyumi of Emory University presented initial Phase 2 data from our PreSERVE-AMI tria.... Read More